Your Notifications
All done, no notifications
Dr. Prof. Andrea Necchi

Dr. Prof. Andrea Necchi

Medical Oncologist ·
, milan, Italy

19 Years of experience ·
Languages Spoken: English, Italian

Book a video consultation with Prof. Andrea Necchi for Medical Oncologist, from USD 503. Receive a signed report within 24 hours or a full refund if unavailable.
USD 503per video consult
Book & Pay – USD 503Chat on WhatsApp Free 15-min Screening

Specialises in:

Bladder cancerMuscle-invasive bladder cancerLocally advanced bladder cancerMetastatic urothelial carcinomaUpper urinary tract urothelial carcinoma, where relevant to his clinical practice

About Dr. Prof. Andrea Necchi

  • Prof. Andrea Necchi is a medical oncologist specialising in genitourinary cancers, including bladder, kidney, prostate, testicular, and penile cancers.
  • He works in the Medical Oncology Unit at IRCCS Ospedale San Raffaele in Milan, Italy, where he directs the Strategic Research Programme in Genitourinary Tumours.
  • He is an Associate Professor of Medical Oncology at Vita-Salute San Raffaele University in Milan.
  • He has extensive clinical and research experience in the multidisciplinary treatment of urological malignancies.
  • He has been a leading investigator in the development of neoadjuvant immunotherapy strategies for muscle-invasive bladder cancer, including research through the PURE-01 clinical trial.
  • His research interests include immunotherapy, targeted therapies, precision oncology, and the development of new treatments for advanced and rare genitourinary cancers.
  • He has experience in clinical trials involving bladder cancer, testicular cancer, penile cancer, kidney cancer, and prostate cancer.
  • His research group conducts clinical and translational studies, including early-phase clinical trials for selected patients with genitourinary malignancies.
  • He is involved in international oncology research and serves on scientific committees for organisations such as the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the European Association of Urology (EAU).
  • He is a co-founder and vice-president of the Global Society of Rare Genitourinary Tumours and has contributed to patient-support initiatives for people affected by bladder and kidney cancers.
  • According to the supplied biography, he has authored or co-authored approximately 570 scientific publications and book chapters.

Conditions treated by Prof. Andrea NECCHI

  • Bladder cancer
  • Muscle-invasive bladder cancer
  • Locally advanced bladder cancer
  • Metastatic urothelial carcinoma
  • Upper urinary tract urothelial carcinoma, where relevant to his clinical practice
  • Kidney cancer
  • Prostate cancer
  • Testicular cancer
  • Penile cancer
  • Advanced or recurrent genitourinary malignancies
  • Rare genitourinary cancers

Area of Interest

  • Genitourinary medical oncology
  • Bladder cancer treatment
  • Neoadjuvant immunotherapy for muscle-invasive bladder cancer
  • Immune checkpoint inhibitors
  • Targeted therapies for urothelial carcinoma
  • Molecular profiling and precision oncology
  • Advanced and metastatic urothelial carcinoma
  • Testicular and penile malignancies
  • Kidney and prostate cancer research
  • Rare genitourinary tumours

Qualification

  • Degree in Medicine and Surgery - University of Milan, Italy, 2004, with honors
  • Specialisation in Medical Oncology - University of Milan, Italy, 2008, with honors

Work Experiences

  • Medical Oncologist - Medical Oncology Unit, IRCCS Ospedale San Raffaele, Milan, Italy
  • Director, Strategic Research Programme in Genitourinary Tumours - IRCCS Ospedale San Raffaele, Milan, Italy
  • Associate Professor of Medical Oncology - Vita-Salute San Raffaele University, Milan, Italy
  • Clinical Research Leadership - Coordination of clinical and translational research programmes in genitourinary malignancies
  • Clinical Trial Investigator - Research into immunotherapy and targeted therapies for bladder and other urological cancers
  • International Research Collaborator - Participation in multicentre clinical studies and international research initiatives in genitourinary oncology.

Certifications (1)

  • Fellow of the American Society of Clinical Oncology (FASCO) - Designated in July 2026, according to the supplied biography.

Memberships (10)

  • American Society of Clinical Oncology (ASCO) - Scientific Committee involvement; designated Fellow of ASCO (FASCO) in July 2026, according to the supplied biography
  • European Society for Medical Oncology (ESMO) - Scientific Committee involvement
  • European Association of Urology (EAU) - Scientific Committee involvement
  • Society of Urologic Oncology (SUO) - Scientific Committee involvement
  • Société Internationale d’Urologie (SIU) - Scientific Committee involvement
  • European Multidisciplinary Urologic Meeting (EMUC) - Scientific Committee involvement
  • Global Society of Rare Genitourinary Tumors - Co-founder and Vice-President
  • European Association of Urology Research Foundation (EAU-RF) – Board member
  • Palinuro (Patients Free from Urothelial Tumors) - Co-founder of the Italian patient-support association
  • ANTURE (National Association of Kidney Tumors) - Collaborator

Ready to Speak with Prof. Andrea Necchi?

Book a secure video consultation for expert Cancer Specialist care.

Book Consultation

What to Expect in Your Consultation

Upload Your Medical Reports

Upload MRI/CT scans, laboratory reports, prescriptions, and previous medical records. Supported formats: PDF, JPEG, and DICOM.

30-Min Video Consultation

Consult the Doctor in your preferred language. A family member or caregiver is welcome to join.

Medical Opinion Within 24 Hours

Receive a signed medical opinion with diagnosis, treatment recommendations, and next steps in a downloadable PDF.

Care Coordination (Optional)

If needed, our team can assist with a second opinion, hospital appointments, or medical travel arrangements.

Procedures Performed

Chemotherapy
Immunotherapy
Kidney Cancer Treatment
Prostate Cancer Treatment

Frequently Asked Questions

Prof. Andrea NECCHI is available to teleconsult on the MediGence platform.

The consultation typically lasts between 15 and 30 minutes. It may exceed the estimated time, depending on the patient’s questions and the doctor's medical recommendations.

We have Medical specialists and board-certified doctors on our panel. The consultation will be organised within 24 to 48 hours, or based on the availability of the doctor and the patient.

No, the follow-up consultation fee is not included in the consultation price. The patient will be required to re-book the consultation.

The option to share your medical records is available between steps in the form provided on the website.

Yes. If you are satisfied with the consultation, you can proceed with treatment packages tailored to your diagnosis, with assistance from our case managers.

Yes. The cost estimate will be provided to you by our case manager, including the doctor’s opinion, the cost estimate, and crucial information about travelling to your medical destination.

FAQ's Related to Medical Oncologist

A medical oncologist specialises in treating cancer using medicines, including chemotherapy, immunotherapy, hormone therapy, and targeted therapy. The treatment approach depends on the cancer type, stage, biological characteristics, and the patient's overall health.

Neoadjuvant immunotherapy is treatment given before the main local treatment, such as surgery, to stimulate the immune system against cancer cells. In bladder cancer, it is an active area of clinical research. Its use depends on the specific clinical setting, current evidence, treatment guidelines, and regulatory approvals.

Immunotherapy uses medicines that help the immune system recognise and attack cancer cells. Immune checkpoint inhibitors are used in certain bladder cancer settings, depending on disease stage, previous treatments, eligibility, and current treatment recommendations.

Targeted therapy acts on specific molecules or pathways involved in cancer growth. For example, erdafitinib may be appropriate for selected patients with advanced urothelial carcinoma whose tumours have qualifying FGFR genetic alterations. Eligibility depends on biomarker testing and the applicable treatment indication.

Metastatic urothelial carcinoma occurs when cancer that began in the urinary tract spreads to distant parts of the body. Treatment may include immunotherapy, chemotherapy, antibody-drug conjugates, targeted therapy, or combinations, depending on the patient's previous treatment, tumour characteristics, and current guidelines.

Phase I trials primarily assess a treatment's safety, dosing, and side effects. Phase II trials investigate preliminary evidence of effectiveness and continue safety assessment. Phase III trials compare a treatment with standard care or another approach in larger patient groups. Eligibility depends on the study protocol and the patient's medical circumstances.

Clinical trials may provide access to investigational treatments or new combinations of existing therapies. However, not every trial is appropriate for every patient, and participation does not guarantee better outcomes. The treating oncologist can discuss potential benefits, risks, alternatives, and eligibility.

Explore Telemedicine Specialists

Please Enquire

Required | alphabets and spaces
Required | A valid, working email address
Required | A valid contact

Not Sure About Your Treatment Plan? Get a Second Opinion

Get your medical reports reviewed by experienced doctors to help you make a confident treatment decision, all online within 48 hours.